|本期目录/Table of Contents|

[1]梁丽斯,李 洁,贺 帅,等.MMP-9、MMP-2及TLR4、HE4对非小细胞肺癌早期诊断意义[J].中华肺部疾病杂志,2024,(05):756-761.[doi:10.3877/cma.j.issn.1674-6902.2024.05.015]
　Liang Lisi,Li Jie,He Shuai,et al.Significance of MMP-9, MMP-2, TLR4, HE4 in early diagnosis of non-small cell lung cancer[J].,2024,(05):756-761.[doi:10.3877/cma.j.issn.1674-6902.2024.05.015]
点击复制

MMP-9、MMP-2及TLR4、HE4对非小细胞肺癌早期诊断意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年05期
页码:
756-761
栏目:
论著
出版日期:
2024-10-25

文章信息/Info

Title:
Significance of MMP-9, MMP-2, TLR4, HE4 in early diagnosis of non-small cell lung cancer
作者:
梁丽斯1; 李 洁2; 贺 帅1; 来艳君1; 刘 铭1; 张 琳1
710054 西安,西安市第九医院检验科1
710054 西安,西安市第九医院呼吸与危重症医学科2
Author(s):
Liang Lisi1;  Li Jie2;  He Shuai1;  Lai Yanjun1;  Liu Ming1;  Zhang Lin1.
1Department of Clinical Laboratory, Xi'an Ninth Hospital Xi'an 710054, China; 2Department of Respiratory and Critical Care Medicine, Xi'an Ninth Hospital Xi 'an 710054, ChinA
关键词:
非小细胞肺癌;  基质金属蛋白酶9;  基质金属蛋白酶2;  Toll样受体4;  人附睾蛋白4;  诊断
Keywords:
Non-small cell lung cancer;  Matrix metalloproteinases 9;  Matrix metalloproteinases 2
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2024.05.015
摘要:
目的 分析血清基质金属蛋白酶9(matrix metalloproteinases-9, MMP-9)、基质金属蛋白酶2(matrix metalloproteinase 2, MMP-2)及Toll样受体4(toll-like receptor 4, TLR4)、人附睾蛋白4(human epididymis protein 4, HE4)用于非小细胞肺癌(non-small cell lung carcinoma, NSCLC)早期诊断的意义。方法 收集2021年1月至2023年12月我院收治的35例NSCLC患者为观察组,选取同期住院肺部良性病变患者39例为对照组。比较两组血清MMP-9、MMP-2、TLR4、HE4水平,比较不同临床病理特征NSCLC患者的血清MMP-9、MMP-2、TLR4、HE4水平。通过受试者工作特征曲线(ROC)分析血清MMP-9、MMP-2、TLR4、HE4单项对NSCLC诊断,采取多因素Logistic回归性分析血清MMP-9、MMP-2及TLR4、HE4与NSCLC的相关性。结果 观察组MMP-9、MMP-2、TLR4、HE4水平[(288.71±92.33)μg/L、(44.46±5.62)pg/ml、(5.30±1.24)ng/ml、(228.76±60.83)pmol/L]高于对照组[(214.66±45.89)μg/L、(20.15±4.03)pg/ml、(2.58±0.84)ng/ml、(57.76±18.14)pmol/L](P<0.05)。TNM分期Ⅲ～Ⅳ期、低分化、淋巴结转移的NSCLC患者血清MMP-9、MMP-2、TLR4、HE4水平高于TNM分期Ⅰ～Ⅱ期、中高分化、无淋巴结转移的NSCLC患者(P<0.05)。经ROC分析,血清MMP-9、MMP-2、TLR4、HE4单项诊断NSCLC的曲线下面积为0.790(95%CI:0.690～0.890)、0.804(95%CI:0.703～0.904)、0.813(95%CI:0.715～0.912)、0.817(95%CI:0.720～0.914),敏感性为0.650(95%CI:0.596～0.712)、0.800(95%CI:0.724～0.870)、0.750(95%CI:0.689～0.834)、0.775(95%CI:0.703～0.852),特异性为0.825(95%CI:0.763～0.884)、0.750(95%CI:0.688～0.825)、0.825(95%CI:0.778～0.871)、0.800(95%CI:0.734～0.846); 血清MMP-9、MMP-2、TLR4、HE4联合诊断NSCLC的曲线下面积为0.953(95%CI:0.912～0.993),敏感性为0.850(95%CI:0.782～0.913),特异性为0.925(95%CI:0.862～0.979)。多因素Logistic回归分析显示,MMP-9≥237.465 μg/L(OR=2.587,95%CI:1.241～5.393)、MMP-2≥29.115 pg/ml(OR=3.129,95%CI:1.336～7.328)、TLR4≥3.870 ng/ml(OR=3.202,95%CI:1.411～7.266)、HE4≥128.030 pmol/L(OR=3.415,95%CI:1.508～7.734)是NSCLC发生的危险因素(P<0.05)。结论 血清MMP-9、MMP-2及TLR4、HE4对NSCLC具有诊断意义。
Abstract:
Objective To analyze the significance of serum matrix metalloproteinases 9(MMP-9), matrix metalloproteinase 2(MMP-2)and toll-like receptor 4(TLR4), human epididymis protein 4(HE4)in early diagnosis of non-small cell lung carcinoma(NSCLC). Methods 35 patients with NSCLC admitted to our hospital from January 2021 to December 2023 were selected as the observation group, and 39 patients with benign lung lesions hospitalized during the same period were selected as the control group. The serum levels of MMP-9, MMP-2, TLR4 and HE4 were compared between the two groups, and the serum levels of MMP-9, MMP-2, TLR4 and HE4 in NSCLC patients with different clinicpathological characteristics were compared. The correlation between serum MMP-9, MMP-2, TLR4 and HE4 for the diagnosis of NSCLC was analyzed by receiver operating characteristic curve(ROC). The correlation between serum MMP-9, MMP-2, TLR4 and HE4 and NSCLC was analyzed by multivariate Logistic regression. Results The levels of MMP-9, MMP-2, TLR4 and HE4 in the observation group[(288.71±92.33)μg/L,(44.46±5.62)pg/ml,(5.30±1.24)ng/ml,(228.76±60.83)pmol/L] were higher than those in the control group [(214.66± 45.89)μg/L, 20.15±4.03)pg/ml,(2.58±0.84)ng/ml,(57.76±18.14)pmol/L](P<0.05). Serum levels of MMP-9, MMP-2, TLR4, and HE4 in NSCLC patients with low-differentiation and lymph node metastasis in TNM stages Ⅲ to Ⅳ were higher than those in patients with medium-differentiation and no lymph node metastasis in TNM stages Ⅰ to Ⅱ(P<0.05). According to ROC analysis, the areas under the curve of serum MMP-9, MMP-2, TLR4 and HE4 for the single diagnosis of NSCLC were 0.790(95%CI: 0.690-0.890), 0.804(95%CI: 0.703-0.904)and 0.813(95%CI: 0.703-0.904). 0.813(95%CI: 0.715-0.912), 0.817(95%CI: 0.720-0.914), the sensitivity was 0.650(95%CI: 0.596-0.712), 0.800(95%CI: 0.724-0.870), 0.750(95%CI: 0.724-0.870), 0.750(95%CI: 0.689- 0.834), 0.775(95%CI: 0.703-0.852), the specificity was 0.825(95%CI: 0.763-0.884), 0.750(95%CI: 0.688-0.825), 0.825(95%CI: 0.778-0.871), 0.800(95%CI: 0.734-0.846); The combined diagnosis of NSCLC with serum MMP-9, MMP-2, TLR4 and HE4 was 0.953(95%CI: 0.912-0.993), sensitivity was 0.850(95%CI: 0.782-0.913), and specificity was 0.925(95%CI: 0.862-0.979). Multivariate Logistic regression analysis showed that MMP-9≥237.465 μg/L(OR=2.587, 95%CI: 1.241-5.393), MMP-2≥29.115 pg/ml(OR=3.129, 95%CI: 1.336-7.328), TLR4≥3.870 ng/ml(OR=3.202, 95%CI: 1.411-7.266), HE4≥128.030 pmol/L(OR=3.415, 95%CI: 1.508-7.734)were the risk factors for NSCLC(P<0.05). Conclusion Serum MMP-9, MMP-2, TLR4 and HE4 are useful in the diagnosis of NSCLC.

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 Xuan J, Peng J, Wang S, et al. Prognostic significance of Naples prognostic score in non-small-cell lung cancer patients with brain metastases[J]. Future Oncol, 2022, 18(13): 1545-1555.
3 Sun H, Liu M, Yang X, et al. Construction and validation of prognostic nomograms for elderly patients with metastatic non‐small cell lung cancer[J]. Clin Respir J, 2022, 16(5): 380-393.
4 Diao X, Guo C, Li S. Lymphatic metastasis in non-small cell lung cancer: recent discoveries and novel therapeutic targets[J]. Cancer Commun(Lond), 2022, 42(12): 1403-1406.
5 龚 珂, 屈佳肴, 刘香婷, 等. 肺癌相关肿瘤标志物研究进展[J]. 医学理论与实践, 2020, 33(5): 713-714,720.
6 Jouida A, O'callaghan M, Mc Carthy C, et al. Exosomes from EGFR-mutated adenocarcinoma induce a hybrid EMT and MMP9-dependant tumor invasion[J]. Cancers(Basel), 2022, 14(15): 3776-3776.
7 Manola I, Mataic A, Drvar DL, et al. Peritumoral clefting and expression of MMP-2 and MMP-9 in basal cell carcinoma of the skin[J]. In Vivo, 2020, 34(3): 1271-1275.
8 Alrehaili AA, Gharib AF, Karam RA, et al. Clinical significance of plasma MMP-2 and MMP-9 levels as biomarkers for tumor expression in breast cancer patients in Egypt[J]. Mol Biol Rep, 2020, 47(2): 1153-1160.
9 Da Cruzl LP, De Souza PO, Dal Prá M, et al. TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(8): 166155.
10 Espiau Romera A, Cuesta Guardiola T, Benito Vielba M, et al. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer[J]. Int J Gynaecol Obstet, 2020, 149(3): 265-268.
11 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2021, 101(23): 1725-1757.
12 Gao Y, Chen J, Zhang J, et al. Radiofrequency ablation of primary non-small cell lung cancer: A retrospective study on 108 patients[J]. J BUON, 2019, 24(4): 1610-1618.
13 Peng L, Deng HY, Wang Y. Surgery should still remain the prior option for treating operable early-stage non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2022, 62(1): ezac327.
14 Chockalingam A, Konstantinidis M, Koo B, et al. Surgical resection, radiotherapy, and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: A systematic review and network meta-analysis[J]. BMJ Open, 2022, 12(6): e057638.
15 解福友, 程 刚, 刘 斌. 增强CT联合肿瘤标志物对盐酸安罗替尼治疗非小细胞肺癌中的疗效评估分析[J]. 中国CT和MRI杂志, 2021, 19(5): 26-29.
16 刘亚杰, 马晓波. 肿瘤标志物GSTP1,CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值[J]. 中国现代医学杂志, 2020, 30(14): 42-46.
17 肖国辉, 厉 娜, 魏 艳, 等. 辐射诱导线粒体功能障碍激活转化生长因子β1通路促进胰腺癌细胞上皮间质转化[J]. 中华放射医学与防护杂志, 2021, 41(6): 407-412.
18 田玉伟, 姜青峰, 王要轩, 等. 巨噬细胞迁移抑制因子,基质金属蛋白酶-9在胆管癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2021, 38(5): 911-914.
19 Xiang Z, Deng X, He W, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy[J]. Ann Med, 2022, 54(1): 1357-1371.
20 凌智君, 邢 龙, 于艳芳. 血清MMP-2、P53抗体检测在非小细胞肺癌患者病情判断中的临床价值及意义[J]. 实用癌症杂志, 2021, 36(2): 228-230,246.
21 莫伟良, 吴森泉, 黎银焕, 等. 喜炎平注射液辅助奥司他韦对急性重症病毒感染性肺炎患者TLR4/NF-κB信号通路及下游炎症因子的影响[J]. 中华医院感染学杂志, 2022, 32(19): 2891-2895.
22 陈 真, 邓森灵, 兰代群, 等. 上皮性卵巢癌患者血清miR-122-5p和HE4及CA125诊断价值[J]. 中华肿瘤防治杂志, 2021, 28(24): 1909-1914.
23 Li W, Wang D. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125[J]. Arch Gynecol Obstet, 2020, 301(5): 1219-1225.
24 刘文楼, 王红梅, 秦晓冰, 等. 血清HE4、VEGF、CYFRA21-1联合检测在非小细胞肺癌诊断中的意义及其与临床病理特征的关系[J]. 徐州医科大学学报, 2020, 40(9): 625-630.
25 王欣欣, 黄松洁, 于 洋, 等. 血清ProGRP, SCCAg及HE4与非小细胞肺癌患者病理特征的关系及其诊断价值分析[J]. 现代生物医学进展, 2020, 20(13): 2497-2501.
26 刘 艳, 周 萍, 高雪梅, 等. miR-221靶向调控QKI-5对卵巢癌SKOV-3细胞上皮-间充质转化影响[J]. 中华肿瘤防治杂志, 2021, 28(10): 740-747,752.
27 许 辉, 沈 杰, 谢兰军. miR-148b-3p通过调控Wnt信号通路对胶质瘤细胞侵袭和迁移的影响[J]. 中华肿瘤杂志, 2020, 42(7): 565-569.
28 程 远, 向 森, 路慧彬. 干扰PTX3表达对甲状腺癌细胞TPC-1增殖、侵袭及TLR4/NF-κB通路蛋白表达的影响[J]. 郑州大学学报(医学版), 2020, 55(3): 355-359.
29 杨庆利, 冷 静. TLR2和TLR4信号在肿瘤发生和发展中的作用及机制的研究进展[J]. 中国免疫学杂志, 2021, 37(3):382-384.
30 汪赛兵, 周美文, 张宜武. 血清CYFRA21-1、HE4水平与非小细胞肺癌患者病理特征和预后的相关性[J]. 西部医学, 2022, 34(7): 1073-1077.
31 O'Rand MG, Widgren EE, Hamil KG, et al. Epididymal protein targets: a brief history of the development of epididymal protease inhibitor as a contraceptive[J]. J Androl, 2011, 32(6): 698-704.
32 Cohen DJ, Maldera JA, Vasen G, et al. Epididymal protein CRISP1 plays different roles during the fertilization process[J]. J Androl, 2011, 32(6): 672-678.
33 Melichar B. Human epididymis protein 4: the start of a post-ROMAn era?[J]. Clin Chem Lab Med, 2012, 50(12): 2069-2073.

备注/Memo

备注/Memo:
基金项目: 陕西省自然科学基础研究计划资助项目(2019JQ-829)
通信作者: 贺 帅, Email: heshuai1171978@163.com
更新日期/Last Update: 2024-10-25